- INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
-
Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
- -
-
Paragraph 001366
(2021/12/28)
-
- New pyrrolidine derivatives, pharmaceutical compositions and uses thereof
-
Pyrrolidine derivatives of the formula and their use as medicaments for the treatment of obesity and type 2 diabetes.
- -
-
Paragraph 0428
(2014/04/18)
-
- NEW PYRROLIDINE DERIVATIVES AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS
-
The invention relates to new pyrrolidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
- -
-
Page/Page column 85; 86
(2014/05/07)
-
- 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES
-
Novel 4-amino-6-(heterocyclic)picolinic acids and their derivatives and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their derivatives are useful to control undesirable vegetation.
- -
-
Paragraph 0260; 0261
(2014/09/29)
-
- NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS
-
The invention relates to new azetidine derivatives of the formula (I) wherein Ar1, Ar2, X, R, T and L are as defined in the description, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
- -
-
Page/Page column 95
(2013/07/05)
-
- AZETIDINE DERIVATIVES
-
Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.
- -
-
Paragraph 0586; 0587
(2013/06/28)
-
- NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
- -
-
Page/Page column 62
(2012/06/30)
-
- Benzodioxoles: Novel cannabinoid-1 receptor inverse agonists for the treatment of obesity
-
The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractabili
- Alig, Leo,Alsenz, Jochem,Andjelkovic, Mirjana,Bendels, Stefanie,Bénardeau, Agnès,Bleicher, Konrad,Bourson, Anne,David-Pierson, Pascale,Guba, Wolfgang,Hildbrand, Stefan,Kube, Dagmar,Lübbers, Thomas,Mayweg, Alexander V.,Narquizian, Robert,Neidhart, Werner,Nettekoven, Matthias,Plancher, Jean-Marc,Rocha, Cynthia,Rogers-Evans, Mark,R?ver, Stephan,Schneider, Gisbert,Taylor, Sven,Waldmeier, Pius
-
p. 2115 - 2127
(2008/12/22)
-
- Heterocyclic CB1 receptor antagonists
-
The present invention relates to compounds of formula wherein R1 and R2 are each independently hydrogen or halogen. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of
- -
-
Page/Page column 8
(2010/11/08)
-
- Stereospecifically substituted benzo[1,3]dioxolyl derivatives
-
The present invention relates to compounds of formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are
- -
-
Page/Page column 10
(2010/11/25)
-
- Spiro-pentacyclic compounds
-
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with
- -
-
Page/Page column 9
(2010/02/13)
-
- NOVEL BENZODIOXOLES
-
The present invention relates to compound of formula (I) Wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.
- -
-
Page 111-112
(2008/06/13)
-
- 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
-
Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
- -
-
-